advertisement - science€¦ · 1portfolio transformation and late-stage clinical development,...
TRANSCRIPT
ADVERTISEMENT
Prevention
The MCS product offices responsible for vaccine and platformtechnology development engaged in multiple efforts to acceleratedevelopment of Ebola vaccine candidates. Of note, the WHO andMédecins Sans Frontières (MSF) utilized the Department of Defense-funded r-VSV∆G-ZEBOV vaccine in a ring vaccination campaign.MCS, in collaboration with the Defense Threat Reduction Agency,provided early testing and development activities for the vaccine.During the exercise, more than 3,000 people were vaccinated.MCS currently maintains a 23,000 multi-dose vial stockpile of theinvestigational vaccines in case additional doses are required.
DiagnosisThe WHO developed a National Laboratory Strategy in response tothe outbreak. As part of this effort, the Defense Biological ProductAssurance Office deployed two co-funded Nebraska StrategicResearch Institute personnel to support sequencing efforts. Thepersonnel took sequencing equipment, consumables, and reagentsto establish a sequencing capability at the Institut National deRecherche Biomédicale within the DRC. This capability sequencedEbola samples from the outbreak so the data can be shared with thebiodefense community on critical reagents for the Ebola virus.
Treatment
MCS’s biological therapeutics office worked closely with the WHOand MSF on their Ebola drug treatment in development. The drugRemdesivir, developed by Gilead Sciences and funded by theDepartment of Defense, was deployed to the DRC for emergencyuse during the outbreak.
In addition, the MCS platform technologies office partnered with theNational Allergy and Infectious Disease Vaccine Research Center torapidly manufacturing their VRC-114 anti-Ebola monoclonal antibodyin support of conducting clinical trials for a vaccine and therapeuticin the DRC. By leveraging the DOD’s existing monoclonal antibodyplatform and Advanced Development and Manufacturing facility
In the past decade, we have seen an increase in infectious diseaseoutbreaks, most notably with the West Africa Ebola outbreak in2014, which left more than 11,000 dead and 17,000 survivors,
many of whom still require post-recovery medical care. The threatcontinues today. Public health officials and business leaders likeBill Gates have long warned that the world is not ready for the nextpandemic.
Global health officials say it’s more imoutbreaks to be stopped at their souepidemics. And that is exactly what tcollaboration with the World Health Oand other international partners—didoutbreak in the Democratic Republic
On May 8, the Ministry of Health of tEbola virus outbreak in Bikoro HealtProvince. A total of 54 cases and 33900 identified contacts. The WHO wgovernment to rapidly scale up its opartners.
Ebola is endemic to the DRC. The laand was quickly contained. The WHquick testing of blood samples, anna rapid response from health author
Department of Defense ResThe Joint Program Executive OfficeRadiological, and Nuclear DefenseProgram Management Office for Me(JPM-MCS) played a significant roleresponse to the recent outbreak. ThDepartment of Defense’s single focafielding of chemical, biological, radiequipment and medical countermea
The JPEO recognized the importanceffort based on its previous and concountermeasures to protect, identifyare utilizing a whole-of-governmentour mission space is ultimately to suimperative to support our domesticpartners in this response,” said Mr.Executive Officer for JPEO-CBRNDcommunity in whatever way we can
Department of DefenseIntegral in the Democratic Republic of the Congo
Ebola Outbreak ResponseBy Dr. Clay Holloway & Hannah Feldman, Medical Countermeasure Systems
platform and anufacturing facility,MCS a C-114 to be
ng Eb ted individuals, t ating FDAoval o a ther p . . s an .
k is cont n rt to t Eort nd ational p
the iul 4. c rdi th s
res te ei i l R
t ginn g of gus . , gs ech isms nd rvivo onit s
ra y mi ate, etec and spo to s s.
OL id Ha mer, oin roj ct na for praartm t’s r on to he utb ak. “ ur t co
gr to tai g t o tbr k. he O’ edicou ea e tio ul e e co rain the
velop by E -CBRND and the O er ot utili . Wec ’t h e provided ort without collab atin ourinter- d intra-agen n , local teams and e inter
O save
--
JPM- e f he U. Defense’s JointProgra l, Radiological, anNuclear i rces and the natiowith safe, i utions to counterchemical, biolog c nuclear threats.
To contact MCS i rnd.list.co unications@m
mportant than ever for diseaserce before they come full-blownthe Department of Defense—inOrganization (WHO), interagencd in response to the latest Ec of the Congo (DRC).
the DRC notified thth Zone in the no st3 deaths were teworked closel thoperations al
atest o ak occu ,HO att ed snoun th anritie
sp e
f h a o l,( e Jo
al nth . enP e
l oi d opi ndgi u r d seure .
of cont tin tued p ald t E v eroach to this r ile
u rt the w ht ia nter p hD las i gr. “ r s g l.”
1Portfolio Transformation and Late-Stage Clinical Development, Biogen, Cambridge, MA;
[email protected] BEST Program and Department of Microbiology and Immunology,
Cornell University, Ithaca, NY; [email protected]
CORNELL
BESTPROGRAM
Phase 3+Exploratory Phase 2Discovery
Research & development technologies
Computation & data analytics
Translational biomarkers
Medical affairs
Assetmanagement
Business analytics
Portfolio management
Drug development pipeline
Regulatory
Clinical developmentProtein engineering
Phase 1
FIGURE 1.
Sessiontopics
For additional information and to explore future opportunitieswith
this drug development trainingmodel,please contact the authors:
[email protected] and [email protected].
*40 Ph.D. students, postdocs, and medical students from Boston University;Cornell University; Emory University; Georgia Institute of Technology; JohnsHopkins University; Meharry Medical College; Michigan State University; NewYork University; Rutgers University; Universities of California at Davis, Irvine,and San Francisco; Universities of Colorado at Anschutz and Denver; Universityof North Carolina at Chapel Hill; University of Massachusetts Medical School;University of Rochester; Vanderbilt University; Virginia Polytechnic Institute andState University; andWayne State University.
Teams receive topics and supportinginformation to generate business case.
Team-building emphasizes value ofshared responsibility.
Feedback assesses impact of conference.
FIGURE 2.
Participants complete preconference surveys toidentify expertise and professional interests.
Session leaders discuss their career paths, current roles,and contributions to project teams.
Teamselection
Topicselection
Tailoredteam
experience+
Conference format
ADVERTORIALPRODUCED BY THE SCIENCE/AAAS CUSTOM PUBLISHING OFFICE
Purposeful outcomesParticipantswere introduced to the drug development process (from
concept to approval), and sessionswere led by individuals from acrossBiogen,who offered insight on their rolesóincluding how they supportproject teams. The topics included asset management, biomarker de-velopment, business and data analytics, clinical development,medicalaffairs, portfolio management, protein engineering, and regulatory af-fairs and policy (Figure 1). In addition, participants served on teams
that generated a business case and recommendations for progressionof a mock project to the next drug development stage (Figure 2).
Reˇning and reframingA new training model is needed to strengthen and reˇne the neces-
sary skills for those who wish to translate new biomedical discoveriesinto beneˇcial drugs. More trainees with the right experience will in-crease the pace of drug development, reducing the burden of debili-tating medical conditions on society. Such a reframing of the trainingexperience will positively change the conduct of science and expandthe ways that meaningful contributions to biomedical science are
deˇned. This conference emphasizes the importance of experientiallearning and serves as amodel for such training.
References
1. G.A. Van Norman, JACC: Basic to Translational Science 1, 170ñ179 (2016).
2. J. R. Katzenbach,D. K. Smith, Harvard Business Review 71, 111ñ120 (1993).
Demand for a qualiˇed biomedical science workforce totackle the challenges of making better medicines remainshigh; however, few scientists and clinicians learn about drug
development during their training. To assist trainees with ap-preciating differences between basic science (understandingdisease mechanisms) and applied science (drug development),Biogen and the Cornell Broadening Experiences in Scientiˇc Train-ing (BEST) program convened a conference in June 2018 at theBiogen headquarters in Cambridge, Massachusetts (#BiogenBESTDDConf2018).
Selection processParticipants were identiˇed primarily from academic institutions with
U.S. National Institutes of Health (NIH) BEST programs (www.nihbest.org;https://commonfund.nih.gov/workforce),as they are familiarwithbiophar-ma career pathways. Trainees* were exposed to key drug developmentquestions, different roles in and out of the laboratory or clinic, and skillsneeded to be successful in biopharma. To ensure that information fromthe conference extendedbeyond thosewho attended,a requirementwasthat trainees share key conceptswith others at their home institutions.
Unique approachThe average time for developing a new drug is approximately 12
years and costs over USD 1 billion, predominantly due to failures ateach stage of drug development (1). An appropriately trained work-force is onemechanism for accelerating timelines and reducing the riskof failure.Asmany biomedical sciences training programs do not offeractivities related to drug development, traineesmust opt for additionalspecialized fellowships (ranging in duration from several weeks to a
few years) or transition to industry with little knowledge of the skillsnecessary to be successful in this sector. As an initiative of BiogenísPortfolio Transformation, a short-term, intensive conference was devel-oped to demystify drug development for academic trainees. The goalwas to create amodel for similar events across the country.High-performing project teams are a hallmark of biopharma, but
are less common in academia (2). Conference activities, therefore, fo-cused on providing participants with a project-team experience thathighlighted key drug development questions; stage-appropriate com-position of project teams; the importance of team dynamics and ofmaximizing the strengths of each member; and how the biopharma
ecosystem supports project teams.
A novel target for accelerating drug development:Biomedical science trainingCherie Butts1 and Avery August2
Kong-YanWKong-YanWu et al. (Zhen-Ge Luo), “Semaphorin 3A activates the guanosine triphosphataseRab5 to promote growth cone collapse and organize callosal axon projections”, Sci. Signal. 7, ra81 (2014).
Rat Brain Slice. Image: Kong-YanWu and Zhen-Ge Luo, Chinese Academy of Sciences.
Stay on top of the
latest advances in brain
development and neurological
disorders with Science
Signaling, the leading online
journal of cross-disciplinary
cell signaling research. The
journal’s high-impact articles
showcase basic research
related to cellular and
organismal regulation relevant
to development, physiology,
and disease as well as applied
signaling research important
for drug discovery and
synthetic biology.
Learn more and submit
your research today:
ScienceSignaling.org
CALL FOR PAPERS!DOES YOUR LAB ANALYZE
THE MECHANISMS THAT
MEDIATE COMMUNICATION
BETWEEN CELLS?
New Version!
Over 75 New Features &Apps in Origin 2018!
25+ years serving the scientific & engineering community
For a FREE 60-dayevaluation, go to
OriginLab.Com/demoand enter code: 7564
Over 500,000 registered users worldwide in:◾ 6,000+ Companies including 20+ Fortune Global 500◾ 6,500+ Colleges & Universities◾ 3,000+ Government Agencies & Research Labs
ENERGY AND SUSTAINABILITY
Energy Storage
ES01 Organic Materials in Electrochemical Energy Storage
ES02 Next-Generation Intercalation Batteries
ES03 Electrochemical Energy Materials Under Extreme Conditions
ES04 Solid-State Electrochemical Energy Storage
Catalysis, Alternative Energy and Fuels
ES05 Cooperative Catalysis for Energy and Environmental Applications
ES06 Atomic-Level Understanding of Materials in Fuel Cells and Electrolyzers
ES07 New Carbon for Energy—Materials, Chemistry and Applications
ES08 Materials Challenges in Surfaces and Coatings for Solar Thermal Technologies
ES10 Rational Designed Hierarchical Nanostructures for Photocatalytic System
ES11 Advanced Low Temperature Water-Splitting for Renewable Hydrogen Production
via Electrochemical and Photoelectrochemical Processes
ES12 Redox-Active Oxides for Creating Renewable and Sustainable Energy Carriers
Water-Energy Materials and Sustainability
ES09 Advanced Materials for the Water-Energy Nexus
ES13 Materials Selection and Design—A Tool to Enable Sustainable Materials
Development and a Reduced Materials Footprint
ES14 Materials Circular Economy for Urban Sustainability
Photovoltaics and Energy Harvesting
ES15 Fundamental Understanding of the Multifaceted Optoelectronic Properties
of Halide Perovskites
ES16 Perovskite Photovoltaics and Optoelectronics
ES17 Perovskite-Based Light-Emission and Frontier Phenomena—
Single Crystals, Thin Films and Nanocrystals
ES18 Frontiers in Organic Photovoltaics
ES19 Excitonic Materials and Quantum Dots for Energy Conversion
ES20 Thin-Film Chalcogenide Semiconductor Photovoltaics
ES21 Nanogenerators and Piezotronics
QUANTUM AND NANOMATERIALS
QN01 2D Layered Materials Beyond Graphene—Theory, Discovery and Design
QN02 Defects, Electronic and Magnetic Properties in Advanced 2D Materials
Beyond Graphene
QN03 2D Materials—Tunable Physical Properties, Heterostructures and Device Applications
QN04 Nanoscale Heat Transport—Fundamentals
QN05 Emerging Thermal Materials—From Nanoscale to Multiscale Thermal Transport,
Energy Conversion, Storage and Thermal Management
QN06 Emerging Materials for Quantum Information
QN07 Emergent Phenomena in Oxide Quantum Materials
QN08 Colloidal Nanoparticles—From Synthesis to Applications
SOFT MATERIALS AND BIOMATERIALS
SM01 Materials for Biological and Medical Applications
SM02 Progress in Supramolecular Nanotheranostics
SM03 Growing Next-Generation Materials with Synthetic Biology
SM04 Translational Materials in Medicine—Prosthetics, Sensors and Smart Scaffolds
SM05 Supramolecular Biomaterials for Regenerative Medicine and Drug Delivery
SM06 Nano- and Microgels
SM07 Bioinspired Materials—From Basic Discovery to Biomimicry
BROADER IMPACT
BI01 High Impact Practice—Increasing Ethnic and Gender Diversification
in Engineering Education
CHARACTERIZATION, PROCESSING AND THEORYCP01 Advances in In Situ Experimentation Techniques Enabling Novel and Extreme
Materials/Nanocomposite Design
CP02 Design and In Situ TEM Characterization of Self-Assembling Colloidal Nanosystems
CP03 Advances in In Situ Techniques for Diagnostics and Synthetic Design
of Energy Materials
CP04 Interfacial Science and Engineering—Mechanics, Thermodynamics,
Kinetics and Chemistry
CP05 Materials Evolution in Dry Friction—Microstructural, Chemical
and Environmental Effects
CP06 Smart Materials for Multifunctional Devices and Interfaces
CP07 From Mechanical Metamaterials to Programmable Materials
CP08 Additive Manufacturing of Metals
CP09 Mathematical Aspects of Materials Science—Modeling, Analysis and Computations
ELECTRONICS AND PHOTONICS
Soft Organic and Bimolecular Electronics
EP01 Liquid Crystalline Properties, Self-Assembly and Molecular Order
in Organic Semiconductors
EP02 Photonic Materials and Devices for Biointerfaces
EP03 Materials Strategies and Device Fabrication for Biofriendly Electronics
EP04 Soft and Stretchable Electronics—From Fundamentals to Applications
EP05 Engineered Functional Multicellular Circuits, Devices and Systems
EP06 Organic Electronics—Materials and Devices
Semiconductor Devices, Interconnects, Plasmonic
and Thermoelectric Materials
EP07 Next-Generation Interconnects—Materials, Processes and Integration
EP08 Phase-Change Materials for Memories, Photonics, Neuromorphic
and Emerging Application
EP09 Devices and Materials to Extend the CMOS Roadmap for Logic
and Memory Applications
EP10 Heterovalent Integration of Semiconductors and Applications to Optical Devices
EP11 Hybrid Materials and Devices for Enhanced Light-Matter Interactions
EP12 Emerging Materials for Plasmonics, Metamaterials and Metasurfaces
EP13 Thermoelectrics—Materials, Methods and Devices
Phoenix, ArizonaApril 22–26, 2019 |
2019 SPRING MEETING & EXHIBIT
CALL FOR PAPERSAbstract Submission Opens
September 28, 2018
Abstract Submission Closes
October 31, 2018
Spring Meeting registrations include MRS Membership July 1, 2019 – June 30, 2020
506 Keystone Drive • Warrendale, PA 15086-7573
Tel 724.779.3003 • Fax 724.779.8313 • [email protected] • www.mrs.org
Meeting Chairs
Yuping Bao The University of Alabama
Bruce Dunn University of California, Los Angeles
Subodh Mhaisalkar Nanyang Technological University
Ruth Schwaiger Karlsruhe Institute of Technology—
Institute for Applied Materials
Subhash L. Shinde University of Notre Dame
Don’t Miss These Future MRS Meetings!
2019 MRS Fall Meeting & Exhibit
December 1–6, 2019, Boston, Massachusetts
2020 MRS Spring Meeting & Exhibit
April 13–17, 2020, Phoenix, Arizona
www.mrs.org/spring2019
new products
31 AUGUST 2018 • VOL 361 ISSUE 6405 929 SCIENCE sciencemag.org/custom-publishing
LIFE SCIENCE TECHNOLOGIES Produced by the Science/AAAS Custom Publishing Office
Glass Media Bottles
PUREGRIP borosilicate glass media bottles
use a cap with a protruding ridge that
improves a userís ability to safely handle
the bottle with gloved hands, especially
when the bottles are wet. The patented
cap is easy to open or close, and provides
����������������������������������
labeling. Constructed of durable
3.3 low-expansion ASTM E438 Type I Class
A borosilicate glass, PUREGRIP bottles come in sizes of 100 mL,
250 mL, 500 mL, 1 L, 2 L, 3 L, 5 L, 10 L, and 20 L. Each bottle in
the product line includes volumetric gradations that have been
���� �������������������������
Foxx Life Sciences
For info: 603-890-3699
www.foxxlifesciences.com
Newly offered instrumentation, apparatus, and laboratory materials of interest to researchers in all disciplines in academic, industrial, and governmental organizations are featured in this
space. Emphasis is given to purpose, chief characteristics, and availability of products and materials. Endorsement by Science or AAAS of any products or materials mentioned is not
implied. Additional information may be obtained from the manufacturer or supplier.
Chemically Competent and Electrocompetent CellsVmax Express is a novel, fast-growing bacterial strain designed
and optimized for high-level recombinant protein expression. This
rationally engineered, next-generation prokaryotic protein expression
system can serve as a replacement for slow-growing Escherichia coli
systems that are prone to low yields and the expression of proteins
as insoluble inclusion bodies. Vmax cells are derived from the marine
microorganism Vibrio natriegens. This gram-negative, nonpathogenic
bacterium has a doubling time twice that of E. coli and produces
three to four times its biomass. Utilizing a robust transcription and
translation system to support this rapid growth rate, Vmax Express
generates more biomass and more recombinant protein per liter
faster. It is compatible with plasmids and antibiotics commonly used
with bacterial expression systems such as E. coli BL21(DE3). Designed
with a tightly controlled, IPTG-inducible T7 promoter system,
Vmax Express cells can be cultured using routine growth medium as
well as commercial autoinduction media, or our Vmax Enriched
Growth Media.
SGI-DNA
For info: 855-474-4362
www.sgidna.com/vmax-express.html
Lentivector Plasmid and Prepackaged VirusSystem Biosciencesí family of Lenti-Labeler constructs facilitate a wide
range of studiesóincluding cell tracking, high-throughput assays, and
������'��&��(��'��(����'���(&���'�&���(��'�'���'�����'���
pLL-CMV-GFP-T2A-Puro Lenti-Labeler construct expresses copepod
�����'��������'����(�'�����'���'���'�����&� (���'��� �'
promoter, which delivers strong expression in most commonly used
cell lines (HeLa, HEK293, HT1080, etc.), and coexpresses the puromycin
resistance gene for selection in vitro prior to in vivo use. Available as
�(����'�����'���&�&�&����'��!����" ��(���'��&��(�'#$%'�
ready-to-transduce prepackaged lentivirus, pLL-CMV-GFP-T2A-Puro
Lenti-Labeler is designed for reliability, so you can get valuable
insights faster.
System Biosciences
For info: 888-266-5066
www.systembio.com
F-Actin Recombinant ProteinAchieve fast staining and immediate functional analysis of
��!������"!�$�"���!�$��"$�"�$ $��"!��"����"����"#$��"$�$�$��"��#"
reagent, LifeAct-TagGFP2 Protein. The addition of this recombinant
protein extends a nontoxic, noninvasive alternative to phalloidin.
F-actin is a key component of the cytoskeleton and is involved
in many important cellular processes, such as cell division, cell
migration, and endocytosis. LifeActóa 17-amino-acid peptide
���$ ��"���"!"����$�"����"$�"��!������$�!���"�$���"��!�$�"
���������"$�"�$ $��"�"����"���!���$"�����"#�$��"��$�����"
���!$�$��"����"!�$�"���!�$��"�� ��!���"#$��"�����"��������"
protein (GFP), it can be conveniently introduced into cells, making
it the ideal tool for F-actin labeling. With LifeAct-TagGFP2 Protein,
scientists can easily transfect living cells, then get brilliant
��������"�$����"$�!���"�"�����!�"��!�$�"���������
for analysis within minutes.
ibidi
For info: 844-276-6363
ibidi.com
Contained Filtration System�������������� �����������������!������!�����!�������������!��
applications where quick cleandowns are required in a multipurpose
production site, or where hazardous materials are being processed
and risk of operator exposure needs to be minimized. The system
���!��������������!�����������������������!�������������������
cartridges enclosed inside two sealed plastic bags, all of which are
contained inside a stainless-steel housing that provides the pressure
�����������!������������������!��������������������!��!����� ���!����
to the production of coatings. Extensive validation testing ensures
��������������!�����������!������������������������� � ������!�
attached even when full of liquid. Filter changeout is quick and
�!���������������������� ��������!��� ��!��������������������!�
and replaced by a new unit, with minimal risk of the operator or
surrounding area encountering the product.
Amazon Filters
For info: +44-(0)-1276-670600
'''�%�%�� �������
Secondary Antibodies Brilliant Violet 421 and Brilliant Violet 480 conjugated secondary
antibodies allow you to add more colors to your multiple labeling
assays in the violetñblue region of the spectrum. When combined with
Alexa Fluor 488, Rhodamine Red-X, and Alexa Fluor 647 conjugates,
�����(��&����� �&��������& %�� (�&(�&���(� ��&��&�� �%�&
counterstaining is desired, four-color antibody staining is possible
using Brilliant Violet 421, Brilliant Violet 480, Alexa Fluor 488, and
Rhodamine Red-X. Switching the nuclear stain from DAPI (emission in
the blue region) to DRAQ5 (which has red emission) frees the violetñ
blue region of the spectrum to accommodate the two Brilliant Violet
�����&���� ��&���(�%�(&%�&��(��(&��� ��&��� %�&����&�
� ��%&� ��&!"#�&$�&���&%&�%��&�&����%��&%�(��(��&��%�&
are recommended for multiple labeling due to their minimal
cross-reactivity.
Jackson ImmunoResearch
For info: 800-367-5296
www.jacksonimmuno.com
Electronically submit your new product description or product literature information! Go to www.sciencemag.org/about/new-products-section for more information.
myIDP: A career plan customized for you, by you.
Visit the website and start planning today!
myIDP.sciencecareers.org
Features inmyIDP include:
§ Exercises to help you examine your
skills, interests, and values.
§ A list of 20 scientific career paths with
a prediction of which ones best fit your
skills and interests.
§ A tool for setting strategic goals for the
coming year, with optional reminders
to keep you on track.
§ Articles and resources to guide you
through the process.
§ Options to savematerials online
and print them for further review
and discussion.
§ Ability to select which portion of your
IDP youwish to share with advisors,
mentors, or others.
§ A certificate of completion for users
that finishmyIDP.
For your career in science, there’s only one
In partnership with:
Recommended byleading professionalsocieties and the NIH
Global bio-techne.com [email protected] TEL +1 612 379 2956 North America TEL 800 343 7475
Europe | Middle East | Africa TEL +44 (0)1235 529449 China [email protected] TEL +86 (21) 52380373
For research use or manufacturing purposes only. Trademarks and registered trademarks are the property of their respective owners.
Learn more | rndsystems.com/antibodies
Get Results The First TimeAnd Every Time
With R&D SystemsÆ
Antibodies